AIDS Research and Therapy

Table 4 The predicted mean CD4+ change of patients treated with AZT and TDF based regimens at JUSH, September 2012 to July 2014

From: Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study

Status	Status	Delta-method		t	[95% CI]	P value
Status	Status	Margins	Standard error	t	[95% CI]	P value
Unexposed	AZT3TC/NVP	319.11	19.34	16.50	281.02,357.20	P < 0.001
Unexposed	AZT/3TC/EFV	281.54	18.39	15.31	245.31,317.77	P < 0.001
Exposed	TDF/3TC/NVP	295.73	18.39	16.08	259.50,331.96	P < 0.001
Exposed	TDF/3TC/EFV	347.65	18.39	18.90	311.42,383.89	P < 0.001

Back to article page

ISSN: 1742-6405

Contact us

Submission enquiries: journalsubmissions@springernature.com